Walgreens Infusion Services to serve as a limited network home infusion provider for Blincyto

DEERFIELD, Ill. — Walgreens on Thursday announced that effective immediately, Walgreens Infusion Services will serve as a limited network home infusion provider for Blincyto (blinatumomab), a therapy for the treatment of patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Blincyto can now be obtained through and administered by Walgreens Infusion Services.

 

“Through our nationwide, community-based infusion services, we deliver comprehensive and collaborative patient care for those with complex conditions and we’re pleased to be able to provide home infusion services to appropriate patients requiring immunotherapy to treat this rare form of ALL,” said Paul Mastrapa, president, Walgreens Infusion Services.

 

Walgreens Infusion Services specially trained infusion nurses and pharmacists treat patients with a wide range of acute, chronic and rare conditions. As the nation’s largest provider of home and alternate treatment site infusion services, Walgreens Infusion Services has more than 90 infusion pharmacies and 110 alternate treatment sites across the country.